Abivax SA Sponsored ADR ABVX 深 沪
已收盘 03-27 16:00:00 美东时间
102.50
-6.980
-6.38%
华盛通- 最 高127.00
- 今 开108.24
- 成交量 175.12万股
- 最 低 102.00
- 昨 收 109.48
- 总市值 0
- 52周最高 148.83
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 4.77
- 委 比 -11.59%
- 总股本 --
- 历史最高 148.83
- 量 比 1.57
- 振 幅 22.84%
- 历史最低 4.77
- 每 手 1
- 风险率 48.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For March 23, 2026
Companies Reporting Before The Bell • Avalo Therapeutics (NASDAQ:AVTX) is likel...
03-23 19:11
'Abivax Denies French Media Report Of Astrazeneca Takeover' - CNBC
https://www.cnbc.com/2026/03/12/abivax-denies-astrazeneca-takeover-.html
03-12 23:02
Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline
AstraZeneca holds exclusive access to Abivax's data room until March 23 as Eli Lilly waits. Key Phase 3 trial results expected in June.
03-12 18:46
Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
Shares of Bark Inc (NYSE:BARK) rose sharply in pre-market trading after a 13D f...
01-12 17:34
6 Healthcare Stocks With Strong Upward Momentum
Out with the old (tech), in with the new (healthcare). After several volatile w...
2025-11-19 01:59
Abivax药物试验成果显著 股价飙升逾550%
美东时间周三早间，法国慢性病生物技术公司Abivax（ABVX）股价暴涨逾550%，因其溃疡性结肠炎治疗药物obefazimod三期临床试验取得积极成果。该公司称，这项试验同时达到主要和次要终点，展现出显著的临床缓解效果。Abivax公司计划在获得更多正面数据后，于明年向美国食品药品监督管理局（FDA）提交新药申请。 海量资讯、精准解读，尽在新浪财经APP 责任编辑：张俊 SF065
2025-07-23 21:40
Abivax Announces Results of its June 6, 2025 Annual General Meeting
Abivax held its 2025 Annual General Meeting on June 6, where shareholders approved all resolutions, including the 2024 financial statements, executive compensation, and board appointments. Sylvie Grégoire was re-elected as Chairman, and Dominik Höchli was appointed to the Board. The Company remains focused on developing treatments for chronic inflammatory diseases.
2025-06-11 20:00
Abivax Presents First Quarter 2025 Financial Results
Abivax在2025年第一季度财务报告中宣布，由于研发费用上升，净亏损扩大至52.4百万欧元。除此之外，公司在第一季度完成了ABTECT 3期试验的入组，并加强了领导层。
2025-06-02 20:00
Abivax Provides Update On Ulcerative Colitis Combination Therapy Program Strategy And Announces Early Preclinical Combination Data Of Obefazimod And Etrasimod In Inflammatory Bowel Disease Mouse Model
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse
2024-09-26 04:04
